Application of a six sigma model to evaluate the analytical performance of urinary biochemical analytes and design a risk-based statistical quality control strategy for these assays: A multicenter study

Qian Liu1 | Guangrong Bian1 | Xinkuan Chen2 | Jingjing Han3 | Ying Chen4 | Menglin Wang5 | Fumeng Yang1

Abstract

Background: The six sigma model has been widely used in clinical laboratory quality management. In this study, we first applied the six sigma model to (a) evaluate the analytical performance of urinary biochemical analytes across five laboratories, (b) design risk-based statistical quality control (SQC) strategies, and (c) formulate improvement measures for each of the analytes when needed.

Methods: Internal quality control (IQC) and external quality assessment (EQA) data for urinary biochemical analytes were collected from five laboratories, and the sigma value of each analyte was calculated based on coefficients of variation, bias, and total allowable error (TEa). Normalized sigma method decision charts for these urinary biochemical analytes were then generated. Risk-based SQC strategies and improvement measures were formulated for each laboratory according to the flowchart of Westgard sigma rules, including run sizes and the quality goal index (QGI).

Results: Sigma values of urinary biochemical analytes were significantly different at different quality control levels. Although identical detection platforms with matching reagents were used, differences in these analytes were also observed between laboratories. Risk-based SQC strategies for urinary biochemical analytes were formulated based on the flowchart of Westgard sigma rules, including run size and analytical performance. Appropriate improvement measures were implemented for urinary biochemical analytes with analytical performance lower than six sigma according to the QGI calculation.

Conclusions: In multilocation laboratory systems, a six sigma model is an excellent quality management tool and can quantitatively evaluate analytical performance and guide risk-based SQC strategy development and improvement measure implementation.
1 | INTRODUCTION

Urinary quantitative biochemical analytes mainly include potassium (K), sodium (Na), chloride (Cl), calcium (Ca), phosphorus (P), glucose (GLU), urea, creatinine (Crea), total protein (TP), and microalbumin (mALB), and their clinical applications are becoming increasingly widespread.1–5 The levels of K, Na, Cl, Ca, and P reflect the excretion and reabsorption functions of the kidneys.6,7 The detection of GLU levels is mainly used for the auxiliary diagnosis of diabetes.8 The levels of urea, Crea, TP, and mALB mainly reflect the degree of kidney damage caused by various diseases.9–11 With the widespread application of urinary biochemical analytes in clinics, the testing capabilities of laboratories are increasingly becoming a challenge. Therefore, laboratories urgently need to design a quality evaluation strategy to evaluate the analytical performance of urinary biochemical analytes.

As an important quality management tool, the six sigma model was first introduced to clinical laboratories by Nevalainen et al.12 to evaluate the performance of an analytical process. As an important parameter for evaluating the analytical performance of laboratories, the sigma metric has a significant advantage in quantitative evaluation.13 Once the analytical performance of the laboratory achieves six sigma, there are only 3.4 errors per one million test results (the defect rate per million is 3.4), and the detection capability of the laboratory has reached the “world-class” level.14 The six sigma model is mainly composed of three variables: the total allowable error (TEa), bias, and coefficient of variation (CV). Bias reflects the trueness of analytes, and CV reflects the imprecision of analytes, both of which represent the analytical performance of the laboratory analytical system. However, TEa is closely related to the quality goal selected by the laboratory and is not directly related to the analytical performance of the analytical system itself.15,16 At the Milan Conference in Europe in 2014, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and other organizations described three models of performance specifications: a model based on clinical results (model 1), a model based on biological variation (model 2), and a model based on state-of-the-art instrumentation (model 3).17 Since the data of model 1 are difficult to obtain, model 2 is widely promoted and applied by laboratories. However, the performance specifications of urinary biochemical analytes have no data about biological variation, so we selected a quality goal of urinary biochemical analytes based on model 3 in the present study. Therefore, we chose the external quality assessment (EQA) standard of China as the quality goal. The data were based on the overall urinary biochemical analyte testing capabilities of laboratories in China. The National Center for Clinical Laboratories of China has collected all the data of laboratories participating in the urinary biochemical analyte proficiency test and finally determined the quality goals (TEa) of each analyte based on the baseline of more than 80% of the laboratories passing the proficiency test.

Previous studies have shown that the six sigma model has been widely used to evaluate the analytical performance of serum biochemical markers, immunological markers, and other analytes and to guide laboratories in designing risk-based SQC strategies and improvement measures.18–22 However, the application of six sigma models in urinary biochemical analytes is rare at present. Therefore, we aimed to use the six sigma model to evaluate the analytical performance of urinary biochemical analytes across five laboratories, design risk-based SQC strategies and quality improvement measures, and provide more accurate and reliable analytical results for clinical application.

2 | MATERIALS AND METHODS

2.1 | Materials

This study was conducted in five laboratories in China, which are simply labeled Lab A, Lab B, Lab C, Lab D, and Lab E. The urinary biochemical analytes involved in this experiment included K, Na, Cl, Ca, P, GLU, urea, Crea, TP, and mALB.

All the experiments were conducted with the AU5800 biochemical analyzer (Beckman Coulter, Brea, USA) detection platform and its original supporting reagents. The internal quality control (IQC) materials were provided by Bio-Rad Laboratories (Bio-Rad Inc., California, USA), including the following two levels: the normal level (level 1, lot: 68581) and high level (level 2, lot: 68582). Additionally, two EQA samples that were similar to the IQC materials were selected and provided by the National Center for Clinical Laboratories of China.

2.2 | Methods

The methods for detecting urinary biochemical analyte levels are briefly described as follows: K, Na, and Cl levels were detected using the indirect ion selective electrode method; Ca levels were detected using the azo-arsonic III method; P levels were detected using phosphomolybdic acid colorimetry; GLU levels were detected using the hexokinase method; urea levels were detected using urease colorimetry; Crea levels were detected using the enzymatic method; TP levels were detected using the dye (pyrophosphore red-molybdate) binding method; and mALB levels were detected using the immunoturbidimetric method.

2.2.1 | Calculation of sigma metrics

Referring to the following formula, \( \text{sigma} = \frac{[\text{TEa} \%] - [\text{bias} \%])}{\text{CV} \%} \), the sigma metrics of each analyte were calculated.23 TEa
represents the quality goal chosen by the laboratory. In the present study, based on the Milan consensus and the fact that the TEa of the urinary biochemical analytes was not provided in the biological variation database, we selected the EQA standard of China as the quality goal according to model 3.24-26

The CV data represent the imprecision of each analyte and were derived from six consecutive months of IQC (two levels) analysis from April to October 2020. The five laboratories all adopted the same IQC scheme, and the operation steps are briefly described as follows: under normal conditions, two levels of IQC were analyzed by the instrument at the same time twice a day, and all the samples were detected in a continuous manner (two levels of IQC were analyzed before sample testing, and when all the samples had been tested, two levels of IQC were analyzed once again); the mean value of each analyte was determined by the laboratory based on actual measurement results, and the mean value provided by the kit manufacturer was used only for reference; the CVs of urinary biochemical analytes for both IQC levels were calculated based on the actual measurement results of each laboratory (Table S1).

Bias represents the trueness of each analyte, and it was determined based on EQA samples of urinary biochemical analytes in 2020.

Two EQA samples with similar analyte concentrations in the IQC materials (level 1 and level 2) were selected. The EQA report provided by the National Center for Clinical Laboratories showed that a total of 140 laboratories, including the five laboratories in this study, used the same analytical platform for the measurement of urinary biochemical analytes. The target value of the urinary biochemical analytes was derived from the average value measured by all the laboratories (n=140). Moreover, each laboratory repeatedly measured the EQA sample five times in the same batch and calculated the single percentage difference according to the following formula. In addition, the average absolute value of the above single percentage difference was defined as the bias of that analyte and used for the calculation of its sigma metrics (Table S2). The formula for calculating bias is briefly described as follows:

\[
\text{Bias}_{i} = \frac{\text{Value}_{\text{measured}} - \text{Value}_{\text{target}}}{\text{Value}_{\text{target}}} \times 100\%.
\]

(n=first, second, third, fourth, and fifth)

\[
\text{Bias}_{\text{average}} = \frac{|\text{Bias}_{\text{first}}| + |\text{Bias}_{\text{second}}| + |\text{Bias}_{\text{third}}| + |\text{Bias}_{\text{fourth}}| + |\text{Bias}_{\text{fifth}}|}{5}.
\]

2.2.2 | Normalized sigma method decision charts for urinary biochemical analytes

The normalized sigma method decision charts were generated through the Laboratory Medicine Information Network website (www.clinet.com.cn). In this study, the analytical performance of each analyte (level 1 and level 2) of the five laboratories was visually displayed in a normalized sigma method decision chart, where the y-axis represents the Bias/TEa (%) and the x-axis represents the CV/TEa (%). This chart was divided into six areas by five diagonal lines. Each area represents the level of the analyte’s analytical performance. The sigma values are as follows from the bottom left to the top right: sigma≥6, 6>sigma≥5, 5>sigma≥4, 4>sigma≥3, 3>sigma≥2, and sigma<2.27

2.2.3 | Designing risk-based SQC strategies and formulating improvement measures

According to the flowchart of Westgard sigma rules, run sizes (Figure 1) and the analytical performance of urinary biochemical analytes were utilized to guide the laboratories in designing a risk-based SQC strategy. In addition, for analytes with analytical performance less than six sigma, it was necessary to calculate the quality goal index (QGI), analyze the reasons for the observed poor performance, and prioritize formulating corresponding improvement measures. The formula for calculating the QGI was as follows:

\[
\text{QGI} = \frac{\text{bias}(\%)}{1.5 \times \text{CV}(\%)}.\]

When the QGI is less than 0.8, the precision is not good and needs to be improved first; when the QGI is more than 1.2, the trueness is not good and needs to be improved first; when the QGI is between 0.8 and 1.2, the precision and trueness are both poor, and corresponding improvement measures need to be taken at the same time.27

3 | RESULTS

3.1 | Sigma metrics for urinary biochemical analytes across five laboratories

In the present study, we evaluated the analytical performance of urinary biochemical analytes in five laboratories based on the six sigma model, and it was observed that when the same analyte was detected at different levels, the sigma levels were different. For example, Lab A showed a sigma level of 11.77 for urinary Cl at IQC level 1, but it was 16.43 at IQC level 2. Moreover, although this study was based on the detection of urinary biochemical analytes with the same analytical platform, its analytical performance showed significant differences among different laboratories. Taking urine urea levels as an example, the analytical performance of Lab B ranged from four sigma to five sigma, the analytical performance of Lab A and Lab D was between five sigma and six sigma, and the analytical performance of Lab C and Lab E both reached six sigma. In addition, this study also found that the analytical performance of urinary Na and Cl in the five laboratories all reached six sigma. However, the analytical performance of urinary P only reached six sigma in Lab A, while the analytical performance of other laboratories was between 4 sigma and 6 sigma. The analytical performance of urinary biochemical analytes in the five laboratories is detailed in Table 1. In addition, the analytical performance of each analyte in the five
laboratories is visually displayed in normalized sigma method decision charts based on the levels of these urinary biochemical analytes (Figures 2 and 3).

### 3.2 Formulation of risk-based SQC strategies and improvement measures

In this study, risk-based SQC strategies were designed based on a flowchart of Westgad sigma rules with run sizes (Figure 1) and the analytical performance of urinary biochemical analyte detection. For example, the sigma metrics of urinary K in Lab A were 5.94 for IQC 1 and 5.97 for IQC 2, so it was recommended that the $1_{3s}/2_{2s}/R_{4s}$ ($N = 2, R = 1$) multirules with a run size of 450 samples be applied as a risk-based SQC strategy for urinary K detection. However, the analytical performance of urinary K (QC 1 and QC 2) in Lab B reached six sigma; therefore, the single rule of $1_{6s}$ ($N = 2, R = 1$) with a run size of 1000 samples was recommended as a risk-based SQC strategy for urinary K. The risk-based SQC strategies of the urinary biochemical analytes for five laboratories are detailed in Table 2.

In addition, we calculated the QGI of the urinary biochemical analytes ($\text{Sigma} < 6$) to further determine the potential factors affecting analytical performance. Taking urinary Ca (Lab C) as an example, its QGI was 1.27 at IQC 1 and 1.47 at IQC 2, indicating that trueness

![Flowchart of Westgard sigma rules with run sizes](cited from website http://www.clinet.com.cn/sigma/pv/#sgm4). Sigma metric = $\frac{\text{TE}_a(\%) - \text{bias}(\%)}{\text{CV}(\%)}$. First, the sigma value of each assay was calculated according to the above formula. Second, according to the sigma scale at the bottom of the flowchart, the corresponding quality control rules, the number of quality control materials (N) and the length of the analytical batch (run size) were selected. "Yes" indicates that the quality control rules were violated, so the results were rejected and corrective measures were taken. "No" indicates that the quality control rules were not violated, so the results were accepted and reported.

| Analyte | TEa | Sigma metrics of Lab A | Sigma metrics of Lab B | Sigma Metrics of Lab C | Sigma metrics of Lab D | Sigma metrics of Lab E |
|---------|-----|------------------------|------------------------|------------------------|------------------------|------------------------|
|         |     | Level 1 | Level 2 | Level 1 | Level 2 | Level 1 | Level 2 | Level 1 | Level 2 | Level 1 | Level 2 | Level 1 | Level 2 |
| K       | 29% | 5.94    | 5.97    | 7.14    | 7.46    | 9.84    | 10.89   | 11.61   | 12.60   | 10.69   | 10.90   |
| Na      | 26% | 13.56   | 16.89   | 16.05   | 17.19   | 17.50   | 18.50   | 11.40   | 12.96   | 9.70    | 11.98   |
| Cl      | 26% | 11.77   | 16.43   | 11.54   | 14.04   | 16.31   | 16.37   | 9.91    | 12.03   | 7.04    | 6.90    |
| Ca      | 31% | 11.23   | 10.23   | 8.44    | 8.58    | 5.66    | 5.98    | 6.03    | 6.74    | 11.98   | 9.86    |
| P       | 23% | 5.14    | 5.77    | 4.77    | 4.98    | 5.71    | 5.73    | 5.90    | 5.71    | 6.16    | 8.13    |
| GLU     | 20% | 11.14   | 13.61   | 6.08    | 6.95    | 5.36    | 5.80    | 5.72    | 5.06    | 5.59    | 5.95    |
| Urea    | 21% | 5.69    | 5.16    | 4.09    | 4.87    | 7.44    | 7.04    | 5.48    | 5.85    | 6.21    | 6.59    |
| Crea    | 17% | 6.16    | 7.78    | 5.27    | 5.87    | 5.24    | 5.80    | 6.06    | 6.39    | 5.25    | 5.67    |
| TP      | 44% | 10.28   | 17.83   | 5.47    | 5.86    | 5.16    | 5.92    | 9.81    | 11.97   | 5.30    | 5.94    |
| mALB    | 30% | 10.63   | 14.61   | 7.03    | 8.40    | 5.05    | 5.85    | 6.16    | 8.67    | 5.55    | 5.83    |

Abbreviations: Ca, calcium; Cl, chloride; Crea, creatinine; GLU, glucose; K, potassium; mALB, microalbumin; Na, sodium; P, phosphorus; TEa, allowable total error, which was derived from the EQA standard of China; TP, total protein.
was the main factor affecting its analytical performance; therefore, it is necessary to improve its trueness first. However, for urinary urea detection in Lab A, since its QGI was less than 0.8 at both IQC levels, precision improvement measures should be conducted first to improve its analytical performance. The improvement measures of the urinary biochemical analytes for the five laboratories are detailed in Table 3.

4 | DISCUSSION

To the best of our knowledge, this study is the first systematic evaluation of the analytical performance of urinary biochemical analytes based on the six sigma model. The urine biochemical analytes included in this study were K, Na, Cl, Ca, P, GLU, urea, Crea, TP, and mALB, which basically cover most of the routine analytes measured in most laboratories. This was a multicenter study involving five laboratories in China, and all the experiments were conducted on the same analytical platform, which minimized the deviation caused by system differences, thereby improving the comparability of analytical results among the different laboratories.

Our study shows that the sigma values differ for different concentrations of a given urinary biochemical analyte. In other words, there is a potential relationship between the analytical performance of the analyte and its concentration. Wang et al.\textsuperscript{28} conducted a single-center study to evaluate the analytical performance of urinary albumin based on sigma metrics, and the results showed that the sigma values of urinary albumin at IQC level 1 and IQC level 2 were 4.28 and 6.14, respectively. Zhou et al.\textsuperscript{29} applied six sigma management to evaluate the analytical performance of 16 clinical biochemical analytes. This study also indicated that the sigma values of clinical biochemical analytes were significantly different at different quality control levels. The results of these previous reports are consistent with the findings of this study, and they all completely
TABLE 2 Risk-based SQC strategies of urinary biochemical assays in five laboratories

| Analyte  | Lab A                      | Lab B                      | Lab C                      | Lab D                      | Lab E                      |
|----------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| K        | 1_{2/1} with N=2 and R=450 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| Na       | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| Cl       | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| Ca       | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| P        | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| GLU      | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| Urea     | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| Crea     | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| TP       | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |
| mALB     | 1_{2/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 | 1_{3/1} with N=2 and R=1000 |

Abbreviations: Ca, calcium; Cl, chloride; Crea, creatinine; GLU, glucose; K, potassium; mALB, microalbumin; Na, sodium; P, phosphorus; TP, total protein; N = levels of quality control; R = number of patient samples run between quality control samples. These IQC programs were the new IQC programs instituted after reviewing the sigma data.
of reducing patient risk in real time. These previous reports and our results have completely demonstrated that the six sigma model, as a simple and practical quality management method, is very beneficial to the design of risk-based SQC strategies in the laboratory. In addition, we also calculated the QGI of the urinary biochemical analytes (Sigma<6) to further identify the main factor that negatively impacts analytical performance, which helps a laboratory establish priorities for enhancing the laboratory’s testing capabilities.

According to the QGI of the present study, we recommend that the laboratory adopt the following measures to improve the laboratory’s testing capabilities: (1) standardize the performance of operating procedures by laboratory personnel and reduce experimental errors caused by human factors; (2) improve the management of the reagents to avoid the alternate use of new and old reagent lots; (3) monitor the reagents cycle of the detection system to reduce system errors; and (4) improve the maintenance of the instrument, replace old parts in a timely fashion, and improve the stability of the detection system. The research carried out by Goel et al.\textsuperscript{36} showed that QGI was very helpful for guiding a laboratory in determining the reasons for the poor performance of routine chemistry analyses and for guiding the adoption of appropriate improvement measures. Peng et al.\textsuperscript{37} also calculated the QGI of assays with sigma values less than 5 and provided clear measures for the improvement of their analytical performance. The above results are consistent with those of our study, and they completely confirmed that QGI, as an important parameter of quality improvement measures, can provide an important reference for the formulation of specific improvement plans for laboratories.

There are several limitations in this study that need to be mentioned. First, TEa, as an important parameter for evaluating the sigma value, is a prerequisite for the efficient operation of the laboratory quality system. As the biological variation data of urinary biochemical analytes cannot be obtained at present, the quality goal of this study was based on model 3 (state of the art), which is the EQA standard of China. The data were based on the statistics of the current laboratory’s testing capabilities. The National Center for Clinical Laboratories of China collected the test results of all laboratories that participated in the proficiency testing activities of urinary biochemical analytes and finally determined the quality goals (TEa) of each analyte based on the baseline of more than 80% of the laboratories passing the proficiency test. Therefore, the sigma value of urinary biochemical analytes is limited by detection technology and cannot provide an objective basis from the perspective of biological variation. Second, as one of the variables of sigma metrics, certified reference materials or reference measurement procedures should be used as the first choice for evaluating the trueness of the analyte. However, for clinical laboratories, reference materials are expensive, and the

### Table 3: The quality goal index and quality improvement measures for urinary biochemical assays with sigma metrics <6

| Analyte | Laboratory | Sigma metrics Level 1 | Sigma metrics Level 2 | QGI Level 1 | QGI Level 2 | Improvement measures |
|---------|------------|-----------------------|-----------------------|-------------|-------------|----------------------|
| K       | Lab A      | 5.94                  | 5.97                  | 0.85        | 1.15        | Imprecision and trueness |
| Ca      | Lab C      | 5.66                  | 5.98                  | 1.21        | 1.47        | Trueness |
| P       | Lab A      | 5.14                  | 5.77                  | 2.61        | 2.44        | Trueness |
| P       | Lab B      | 4.77                  | 4.98                  | 4.76        | 3.68        | Trueness |
| P       | Lab C      | 5.71                  | 5.73                  | 1.61        | 2.22        | Trueness |
| P       | Lab D      | 5.90                  | 5.71                  | 1.79        | 1.36        | Trueness |
| GLU     | Lab C      | 5.36                  | 5.80                  | 4.46        | 4.96        | Trueness |
| GLU     | Lab D      | 5.72                  | 5.06                  | 2.25        | 1.35        | Trueness |
| GLU     | Lab E      | 5.59                  | 5.95                  | 1.73        | 1.56        | Trueness |
| Urea    | Lab A      | 5.69                  | 5.16                  | 0.23        | 0.35        | Imprecision |
| Urea    | Lab B      | 4.09                  | 4.87                  | 1.71        | 1.30        | Trueness |
| Urea    | Lab D      | 5.48                  | 5.85                  | 1.53        | 1.72        | Trueness |
| Crea    | Lab B      | 5.27                  | 5.87                  | 1.71        | 3.00        | Trueness |
| Crea    | Lab C      | 5.24                  | 5.80                  | 1.23        | 1.43        | Trueness |
| Crea    | Lab E      | 5.25                  | 5.67                  | 0.99        | 0.92        | Imprecision and trueness |
| TP      | Lab B      | 5.47                  | 5.86                  | 2.05        | 2.60        | Trueness |
| TP      | Lab C      | 5.16                  | 5.92                  | 4.28        | 4.63        | Trueness |
| TP      | Lab E      | 5.30                  | 5.94                  | 4.40        | 3.16        | Trueness |
| mALB    | Lab C      | 5.05                  | 5.85                  | 3.15        | 2.95        | Trueness |
| mALB    | Lab E      | 5.55                  | 5.83                  | 2.08        | 2.01        | Trueness |

Abbreviations: Ca, calcium; Cl, chloride; Crea, creatinine; GLU, glucose; K, potassium; mALB, microalbumin; Na, sodium; P, phosphorus; QGI, quality goal index; TP, total protein.
feasibility of reference measurement procedures is insufficient. Therefore, referring to our previous studies, 27,38 EQA specimens and feedback data provided by the National Center for Clinical Laboratories were used to evaluate the trueness of urinary biochemical analytes. It should be noted that the target values of urinary biochemical analytes obtained in this study were not the true values but were derived from the average values calculated by all the laboratories that participated in the EQA program. Third, this was a cross-sectional study, and there was no evaluation of the analytical performance in the five laboratories after the improvement measures were implemented, but the analytical performance of the analytes was dynamically changing. Therefore, we will continue to collect follow-up data to provide additional reference information for the application of the six sigma model in laboratory quality management.

5 | CONCLUSIONS

In conclusion, this is the first application of the six sigma model to quantitatively evaluate the analytical performance of urinary biochemical analytes and design risk-based SQC strategies and quality improvement measures in five laboratories. It was confirmed that the six sigma model can be used as an important quality management tool to promote the continuous improvement of laboratory testing capabilities.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTEREST

The authors declare that they have no potential competing financial interests or personal relationships that could have appeared to influence the study reported in this article.

AUTHOR CONTRIBUTIONS

QL and FMY conceived and designed the experiments. QL, GRB, XKC, JJH, YC, and MLW performed the experiments. QL and GRB analyzed the data. QL and FMY wrote the first draft of the manuscript. All the authors reviewed and edited the manuscript and approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT

Data are available on request from the authors.

ORCID

Fumeng Yang https://orcid.org/0000-0002-2636-7340

REFERENCES

1. Peng S, Wang J, Xiao Y, et al. The association of carotid artery atherosclerosis with the estimated excretion levels of urinary sodium and potassium and their ratio in Chinese adults. Nutr J. 2021;20(1):50.
2. Feng X, Zheng Y, Guan H, et al. The association between urinary glucose and renal uric acid excretion in non-diabetic patients with stage 1-2 chronic kidney disease. Endocr Res. 2021;46(1):28-36.
3. Ren J, Stankovic A, Knaus D, Phillips S, Knyor D, Buckey J. Urinary calcium for tracking bone loss and kidney stone risk in space. Aerosp Med Hum Perform. 2020;91(9):689-696.
4. Pérez V, Barrera G, Hirsch S, Lorca E, Bunout D. Efficacy of urine urea nitrogen measurement to assess the compliance with protein restricted diets. Nutr Hosp. 2019;36(3):714-717.
5. Mertens B, Verhofstede S, Abramowicz D, Couttenye M. A surprising journey into the conversion of urinary protein creatinine ratio to urinary albumin creatinine ratio as needed in the Kidney Failure Risk Equation. Clin Kidney J. 2021;14(5):1481-1482.
6. Judge C, O’Donnell M, Hankey G, et al. Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): a case-control study. Am J Hypertens. 2021;34(4):414-425.
7. Marwaha R, Garg M, Dang N, et al. Reference range of random urinary calcium creatinine ratio in North Indian children and adolescents. Ann Pediatr Endocrinol Metab. 2019;24(1):34-40.
8. Itano Y, Sobajima H, Ohashi N, et al. High urinary glucose is associated with improved renal prognosis in patients with diabetes mellitus. J Diabetes Investig. 2021;12(6):998-1006.
9. Tsai C, Huang H, Tien N, et al. Longitudinal progression trajectory of random urine creatinine as a novel predictor of ESRD among patients with CKD. Clin Chim Acta. 2019;489:144-153.
10. Kanno H, Kanda E, Sato A, Sakamoto K, Kanno Y. Estimation of daily protein intake based on spot urine urea nitrogen concentration in chronic kidney disease patients. Clin Exp Nephrol. 2016;20(2):258-264.
11. Fellström B, Helmersson-Karlqvist J, Lind L, et al. Albumin urinary excretion is associated with increased levels of urinary chemokines, cytokines, and growth factors levels in humans. Biomolecules. 2021;11(3):396.
12. Nevalainen D, Berte L, Kraft C, Leigh E, Picaso L, Morgan T. Evaluating laboratory performance on quality indicators with the six sigma scale. Arch Pathol Lab Med. 2000;124(4):516-519.
13. Huang Y, Zhang T, Zhao H, et al. Performance evaluation of HbA1c measurement systems with sigma metric for 1066 laboratories in China. Clin Chim Acta. 2018;487:281-286.
14. Dido V, Ćorić J, Mujić J, Panjeta M, Bodulović A, Marjanović M. Determination of six sigma metric in control of enzymes determination in human serum. Clinical Laboratory. 2019;65(7).
15. Varela B, Pacheco G. Comprehensive evaluation of the internal and external quality control to redefine analytical quality goals. Biochimica Medica. 2018;28(2):020710.
16. Liu Q, Fu M, Yang F, et al. Application of Six Sigma for evaluating the analytical quality of tumor marker assays. J Clin Lab Anal. 2019;33(2):e22682.
17. Ceriotti F, Fernandez-Calle P, Klee G, et al. Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM Strategic Conference. Clin Chem Lab Med. 2017;55(2):189-194.
18. Mao X, Shao J, Zhang B, Wang Y. Evaluating analytical quality in clinical biochemistry laboratory using Six Sigma. Biochimica Medica. 2018;28(2):020904.
19. Yang F, Wang W, Liu Q, et al. The application of Six Sigma to perform quality analyses of plasma proteins. Ann Clin Biochem. 2020;57(2):121-127.
20. Bozkaya G, Uzunca N, Bilgili S, Demirezen O. Evaluation of analytical performance of variant II turbo HbA1c analyzer according to sigma metrics. J Med Biochem. 2019;38(1):33-37.
21. Liu Y, Cao Y, Liu X, Wu L, Cai W. Evaluation of the analytical performance of endocrine analytes using sigma metrics. J Clin Lab Anal. 2021;35(1):e23581.
22. Nar R, Emekli D. The evaluation of analytical performance of immunoassay tests by using Six-sigma method. J Med Biochem. 2017;36(4):301-308.

23. Guo X, Zhang T, Gao X, et al. Sigma metrics for assessing the analytical quality of clinical chemistry assays: a comparison of two approaches: Electronic supplementary material available online for this article. Biochemia Medica. 2018;28(2):020708.

24. Panteghini M, Sandberg S. Total error vs. measurement uncertainty: the match continues. Clin Chem Lab Med. 2016;54(2):195-196.

25. EFLM. List of matrices with biological variation datasets. 2021. https://biologicalvariation.eu/bv_specifications/measurand

26. The External Quality Assessment Plan. 2020. https://www.nccl.org.cn/ptCn

27. Liu Q, Zhu W, Bian G, Liang W, Zhao C, Yang F. Application of the sigma metrics to evaluate the analytical performance of cystatin C and design a quality control strategy. Ann Clin Biochem. 2021;58(3):203-210.

28. Wang H, Ma Y, Shan X. Evaluating the analytical quality control of urinary albumin measurements using sigma metrics. Clin Biochem. 2019;73:109-111.

29. Zhou B, Wu Y, He H, Li C, Tan L, Cao Y. Practical application of Six Sigma management in analytical biochemistry processes in clinical settings. J Clin Lab Anal. 2020;34(1):e23126.

30. Fasano T, Bedini J, Fle P, et al. Multi-site performance evaluation and Sigma metrics of 20 assays on the Atellica chemistry and immunoassay analyzers. Clin Chem Lab Med. 2019;58(1):59-68.

31. Taher J, Cosme J, Renley B, Daghfal D, Yip P. A novel Sigma metric encompasses global multi-site performance of 18 assays on the Abbott Alinity system. Clin Biochem. 2019;63:106-112.

32. Westgard J, Westgard S. Quality control review: implementing a scientifically based quality control system. Ann Clin Biochem. 2016;53:32-50.

33. Westgard S, Petrides V, Schneider S, Berman M, Herzogenrath J, Orzechowski A. Assessing precision, bias and sigma-metrics of 53 measurands of the Alinity ci system. Clin Biochem. 2017;50(18):1216-1221.

34. Westgard J. A total quality-control plan with right-sized statistical quality-control. Clin Lab Med. 2017;37(1):137-150.

35. Zeng Y, He H, Qin K, Zhang M, An Z, Huang H. Practical application of the sigma-metric run size nomogram for multistage bracketed statistical quality control analysis of eight enzymes. Clin Chim Acta. 2019;492:57-61.

36. Goel P, Malik G, Prasad S, Rani I, Manhas S, Goel K. Analysis of performance of clinical biochemistry laboratory using Sigma metrics and Quality Goal Index. Practic Lab Med. 2021;23:e00195.

37. Peng S, Zhang J, Zhou W, Mao W, Han Z. Practical application of Westgard Sigma rules with run size in analytical biochemistry processes in clinical settings. J Clin Lab Anal. 2021;35(3):e23665.

38. Liu Q, Chen X, Han J, et al. Application of a six sigma model to the evaluation of the analytical performance of serum enzyme assays and the design of a quality control strategy for these assays: a multicentre study. Clin Biochem. 2021;91:52-58.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Liu Q, Bian G, Chen X, et al. Application of a six sigma model to evaluate the analytical performance of urinary biochemical analytes and design a risk-based statistical quality control strategy for these assays: A multicenter study. J Clin Lab Anal. 2021;35:e24059. https://doi.org/10.1002/jcla.24059